LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global cholangiocarcinoma therapeutics market since 2018, and the market is poised to grow by USD 82.56 million during 2019-2023, progressing at a CAGR of almost 6% during the forecast period. Request free sample pages
Read the 120-page report with TOC on “Cholangiocarcinoma Therapeutics Market Analysis Report by Type (intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023”.
The growing use of combination therapy and the need for drugs with minimal side-effects is anticipated to boost the growth of the cholangiocarcinoma therapeutics market.
The market is witnessing an increase in the use of combination therapies for the treatment of the disease. This is because combination drugs overcome various limitations of each drug, thereby improving their efficacy in treating the disease. For instance, PLATINOL by Bristol-Myers Squibb Company works on stopping the multiplication of cancer cells in the body. GEMZAR by Eli Lily and Company hinders the production of both DNA and RNA, thereby reducing the ability of cancer cells to repair themselves. The combination of these two drugs is currently being used with radiation therapy to eradicate cancer cells in the body completely. Therefore, the growing use of combination therapy is crucial in driving the growth of the market.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Cholangiocarcinoma Therapeutics Market Companies:
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates its business through the BioPharmaceuticals segment. The segment is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative medicines. PLATINOL is the key offering of the company.
Eli Lilly and Company
Eli Lilly and Company operates its business through segments such as Human pharmaceutical products and Animal health products. GEMZAR is the key offering of the company. It is an intravenously administered chemotherapy approved for the treatment of various oncology indications.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd operates its business through segments such as Pharmaceuticals and Diagnostics. XELODA, a capecitabine-based therapy approved for the treatment of various oncology indications, is the key offering of the company.
Pfizer Inc. operates its business through segments such as Innovative health and Essential health. BOSULIF is the key offering of the company, and it is being developed for the treatment of cholangiocarcinoma.
Sanofi operates its business through segments such as Pharmaceuticals, Consumer Healthcare, and Vaccines. ELOXATIN, chemotherapy approved for the treatment of unresectable or recurrent cholangiocarcinoma, is the key offering of the company.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Cholangiocarcinoma Therapeutics Type Outlook (Revenue, USD Million, 2019 - 2023)
- Intrahepatic cholangiocarcinoma
- Extrahepatic cholangiocarcinoma
Cholangiocarcinoma Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare are:
Global Adrenocortical Carcinoma Drugs Market – Global adrenocortical carcinoma drugs market by type (chemotherapy and targeted therapy) and geography (Asia, Europe, North America, and ROW).
Global Cancer Stem Cell Therapeutics Market – Global cancer stem cell therapeutics market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org